BMTC Business Summary

Bio-Medical Carbon Technology Co., Ltd. (BMTC), listed as 4116.TWO on the Taipei Exchange, operates as a specialized medical device manufacturer focused on the development and commercialization of advanced wound care solutions. The company generates revenue primarily through the global sale of its proprietary silver-activated carbon fiber wound dressings, marketed under brands such as KoCarbonAg, KoCarbon, and KoCare. Its business model is vertically integrated, spanning R&D, manufacturing, and international distribution across the United States, Europe, China, and Southeast Asia. BMTC's primary segments include antimicrobial wound care, scar management, and specialized dressings for veterinary use. In the competitive landscape of Taiwan's biotechnology sector, BMTC competes directly with TaiDoc Technology, BenQ Materials (through its Anscare brand), and ACRO Biomedical, positioning itself as a high-end niche provider of biocompatible, odor-reducing, and infection-control materials for chronic and non-healing wounds. BMTC is led by Chairman and Representative Chang Chiao-Feng (Joe Chang), who oversees the company's strategic direction and global expansion. The leadership team is characterized by a strong background in clinical medicine and material science, reflecting the company's 2010 founding as a collaborative effort between multidisciplinary researchers. As of early 2026, the board of directors includes key members such as Li Jing-Min and Lu Jian-An, following a leadership refresh in late 2025 that brought in new expertise to support the company's transition into next-generation biosynthetic materials. The company is backed by significant overseas Chinese and foreign institutional investment, maintaining a focus on rigorous clinical validation and international patent protection to sustain its competitive advantage in the global medical grade carbon fiber market.